Matinas BioPharma
MTNB · Nasdaq · United States
Share price · MTNB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MTNB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Sep 2026+1481.2%
- 20 Aug 2026-24.3%
Nothing announced by MTNB that day or the session before.
- 27 Jul 2026+37.5%
- 14 Jul 2026-27.1%
- 13 Jul 2026-36.4%
- 10 Jul 2026+20.4%
Nothing announced by MTNB that day or the session before.
- 18 Jun 2026-14.9%
Nothing announced by MTNB that day or the session before.
- 20 May 2026+14.5%
Nothing announced by MTNB that day or the session before.
- 23 Apr 2026+10.2%
Nothing announced by MTNB that day or the session before.
- 31 Mar 2026-11.8%
Nothing announced by MTNB that day or the session before.
Share of unusual movement by asset
For each asset, the share of MTNB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Amphotericin B (MAT2203)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 99% |
| Sessions with no dated event | — | 1% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Ergosterol (fungal cell membrane)Small molecule | Cryptococcal Meningitis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | — | $0.8M | $1.3M-$1.8M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | — | $2.4M | $1.9M-$1.6M operating cash flow | report ↗ |
| 2025-Q3 | — | — | $5.4M | $1.5M-$1.5M operating cash flow | report ↗ |
| 2025-Q2 | — | — | $6.5M | $5.3M-$2.0M operating cash flow | report ↗ |
| 2025-Q1 | — | $0.1M | $6.9M | $1.7M-$2.0M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.2M | $10M+ $0.5M short-term inv. | $4.3M-$3.5M operating cash flow | report ↗ |
| 2024-Q2 | — | $3.4M | $4.2M+ $10M short-term inv. | $5.7M-$3.1M operating cash flow | report ↗ |
| 2024-Q1 | — | $3.5M | $1.1M+ $7.0M short-term inv. | $5.8M-$5.8M operating cash flow | report ↗ |
| 2023-Q3 | — | $3.3M | $6.4M+ $12M short-term inv. | $6.1M-$4.4M operating cash flow | report ↗ |
| 2023-Q2 | — | $3.6M | $9.7M+ $13M short-term inv. | $6.1M-$2.2M operating cash flow | report ↗ |
| 2023-Q1 | $1.1M | $4.0M | $5.7M+ $19M short-term inv. | $5.5M-$4.1M operating cash flow | report ↗ |
| 2022-Q3 | $1.1M | $3.7M | $11M+ $22M short-term inv. | $5.5M-$5.0M operating cash flow | report ↗ |
| 2022-Q2 | $1.1M | $4.1M | $10M+ $28M short-term inv. | $5.9M-$5.1M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.0M | $19M+ $25M short-term inv. | $6.0M-$4.8M operating cash flow | report ↗ |
| 2021-Q3 | — | $4.6M | $25M+ $29M short-term inv. | $6.8M-$5.8M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $0.1M | $4.0M | $2.6M-$7.0M operating cash flow | report ↗ |
For fiscal year 2025, Matinas BioPharma did not disclose revenue. R&D spend was $0.09M, down 99.2% YoY. Cash and equivalents were $4M, with a reported net loss of $10.34M and a quarterly net burn of $10.35M.
Matinas is a clinical-stage biopharmaceutical company focused on its lipid nanocrystal platform and lead candidate MAT2203. Following an 80% workforce reduction in late October 2024, the company paused further clinical development and is seeking partners for MAT2203; it has noted that a partnership or additional capital would be required before commencing the planned Phase 3 ORALTO trial. Key disclosed events include continued FDA engagement, support for the compassionate use program, and 2025 financing activity, including a February 2025 securities purchase agreement with gross proceeds of $3.3M.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $11M | $7.3M | $6.1M-$16M operating cash flow | report ↗ |
| 2023-FY | $1.1M | $14M | $4.8M+ $9.0M short-term inv. | $5.7M-$15M operating cash flow | report ↗ |
| 2022-FY | $3.2M | $17M | $6.8M+ $22M short-term inv. | $5.3M-$19M operating cash flow | report ↗ |
| 2021-FY | <$0.1M | $15M | $21M+ $29M short-term inv. | $5.8M-$15M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-06 | D An Evelyn · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-11-06 | NEUGEBOREN EDWARD · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-11-06 | Murphy Keith · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-11-06 | NEUGEBOREN EDWARD · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-11-06 | D An Evelyn · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-11-06 | Murphy Keith · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-07-10 | STERN ADAM K · 10% owner | Option exercise | 344,710 | $0.35 | $121K | Form 4 |
| 2026-07-10 | STERN ADAM K · 10% owner | Option exercise | 630,335 | $0.35 | $221K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 28 reporting institutions held 0.4M shares ($177K, 2.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 65,170 | $33K |
| 2 | CITADEL ADVISORS LLC | 51,698 | $26K |
| 3 | BlackRock, Inc. | 49,650 | $25K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 40,110 | $20K |
| 5 | Holos Integrated Wealth LLC | 32,480 | $16K |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 28,570 | $14K |
| 7 | XTX Topco Ltd | 20,706 | $10K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 18,277 | $9K |
| 9 | STATE STREET CORP | 15,322 | $8K |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 14,328 | $7K |
| 11 | Sargent Investment Group, LLC | 12,720 | $6K |
| 12 | Tower Research Capital LLC (TRC) | 2,853 | $1K |
| 13 | Vanguard Global Advisers, LLC | 1,338 | $669 |
| 14 | MORGAN STANLEY | 344 | $172 |
| 15 | Costello Asset Management, INC | 200 | $100 |